PARSHALL B LYNNE 4

What Happened
Parshall B. Lynne, a director of Cytokinetics, received equity awards on May 27, 2026. The Form 4 reports an acquisition of 2,851 shares at $0.00 and a separate acquisition of 4,301 derivative shares at $0.00 (both recorded as "A" — award/grant). The filing lists no cash consideration; total reported cash value for both line items is $0.00.

Key Details

• Transaction date: 2026-05-27 for both awards.
• Price: $0.00 per share for both grants (typical for restricted stock/awards).
• Amounts: 2,851 shares (direct award) and 4,301 derivative shares (award of a derivative/stock-settled instrument).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes/plan details: the second grant is identified as a "derivative" in the filing — this commonly indicates RSUs, performance shares, or other equity-settled instruments that may vest later. No 10b5-1, tax-withholding, or late-filing indications were reported; the Form 4 was filed the same day as the reported transaction.

Context
These entries are compensation awards to a director rather than open-market purchases or sales. Awards recorded at $0.00 are standard for stock grants and do not by themselves signal a personal cash investment or an immediate bullish/bearish trading intent. Retail investors may watch for future vesting or subsequent sales by the insider for more direct signals of conviction.